About Sterling Biotech
Sterling Biotech is a Healthcare company based in Mumbai (India) founded in 1985, and was acquired by Perfect Day in April 2022. Manufacturer and supplier of fermentation based and synthetic APIs. The company has 249 employees. Its Indian entity Sterling Biotech Limited reported revenue of ₹548 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed competitors have raised funding.
Company details
Sterling Biotech is a drug API manufacturer. The company also manufactures gelatin from animal bones. Their capabilities include a research centre, pilot plant for scale up studies, facility of bioreactors and a range of down streaming process equipments. The Company produces various pharmaceutical products, such as Lovastatin, a cholesterol lowering drug, and oncology products. Its anti-cancer products include DOXO Rubicin, an anti-cancer chemotherapy drug; IDARUBICIN, an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug; Daunorubicin, which is used to treat acute lymphocytic and myelocyticleukemias; IMATINIB, a drug used to treat certain cancers, and EPI Rubicin, an anthracycline drug used for chemotherapy. The Companys other products include DACARBAZINE, which is used to treat Hodgkin disease and malignant melanoma; Temozolamide, an oral alkylating agent used for the treatment of Grade IV astrocytoma, and Simvastatin, a lipid lowering drug. Sterling Biotechs manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting CEP for the active pharmaceutical ingredient Epirubicin , Lovastatin;
- Headquarters Mumbai, India
- Employees 249
- Stage Acquired
- SectorsHealthcare
- Website sterlingbiotech.in
- Social LinkedIn
- Acquired by Perfect Day (Apr 2022)
- Legal Name Sterling Biotech Limited
- Date of Incorporation 23 Mar, 1985
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹548 Cr
FY 2025 · +3% YoY
- Net Profit₹30.23 Cr
FY 2025 · 4% margin
- EBITDA₹137 Cr
FY 2025 · 18% margin
- Investors
- Employee Count249
- Acquired byPerfect Day
(Apr 2022)
Associated legal entities of Sterling Biotech
Sterling Biotech operates through Sterling Biotech Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sterling Biotech Limited Listed CIN L51900MH1985PLC035738 | Active | 23 Mar 1985 | Mumbai, Maharashtra | ₹548 Cr | 249 | 8 | View details |
Investors in Sterling Biotech
Sterling Biotech has secured backing from 1 investor. Prominent investors backing the company include Perfect Day.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Dairy alternatives are produced via fermentation of plant-based sugars. | 2014 | perfectday.com | Berkeley, United States |
Investor details for Sterling Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sterling Biotech Limited (Sterling Biotech)
Sterling Biotech Limited is the primary company behind Sterling Biotech. The board of Sterling Biotech Limited currently have 6 directors; the longest-serving is Vishal Jyotindra Gor, appointed in 2024. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishal Jyotindra Gor DIN 08787850 | Nominee Director | 29 Aug 2024 | 2 yrs 1 mo | Sterling Biotech Limited |
| Keyur Anilkumar Parekh DIN 08868570 | Nominee Director | 29 Aug 2024 | 2 yrs 1 mo | Sterling Biotech Limited |
| Alok Kumar Garg DIN 10630493 | Nominee Director | 29 Aug 2024 | 2 yrs 1 mo | Sterling Biotech Limited |
| Monisha Prabhu Macedo DIN 00144660 | Nominee Director | 24 Mar 2025 | 1 yr 7 mo | Sterling Biotech Limited |
| Aftab Mathur DIN 06594968 | Nominee Director | 25 Jun 2025 | 1 yr 4 mo | Sterling Biotech Limited |
| Priyadarshan Kumar Singh DIN 11606849 | Additional Director | 24 Mar 2026 | 7 mo | Sterling Biotech Limited |
Financials of Sterling Biotech
Figures of Sterling Biotech Limited, the primary company behind Sterling Biotech, for FY 2025. Revenue was ₹548 Cr (+3% year on year). Net profit was ₹30.23 Cr (4% margin). EBITDA was ₹137 Cr (18% margin).
- ₹548 CrRevenue · FY 2025 · +3% YoY
- ₹30.23 CrNet profit · 4% margin
- ₹137 CrEBITDA · 18% margin
- ₹643 CrPaid-up capital
- 249Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Sterling Biotech Limited are on its company page.
Detailed financial statements for Sterling Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Sterling Biotech
3 dated milestones of Sterling Biotech across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Sterling Biotech is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Perfect Day.
Competitors of Sterling Biotech
Sterling Biotech has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed competitors of Sterling Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sterling Biotech
The website of Sterling Biotech (sterlingbiotech.in) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 22.4% vs previous month
Websites whose visitors overlap most with Sterling Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
quantifiedstrategies.com | quantifiedstrategies.com | 100% | #238,344 | – | |
| dolphintrader.com | 100% | #899,263 | View details | ||
forexstrategiesresources.com | forexstrategiesresources.com | 100% | #517,078 | – | |
fxcracked.com | fxcracked.com | 100% | #2,050,564 | – | |
quotatium.com | quotatium.com | 100% | #4,392,106 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Sterling Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Sterling Biotech (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sterling Biotech
Complete news archive for Sterling Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sterling Biotech
Sterling Biotech was founded in 1985.
Sterling Biotech is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Sterling Biotech has 249 employees.
The primary company behind Sterling Biotech, Sterling Biotech Limited, reported revenue of ₹548 Cr for FY 2025, up 3% year on year.
Sterling Biotech is a drug API manufacturer. The company also manufactures gelatin from animal bones. Their capabilities include a research centre, pilot plant for scale up studies, facility of bioreactors and a range of down streaming process equipments. The Company produces various pharmaceutical products, such as Lovastatin, a cholesterol lowering drug, and oncology products. Its anti-cancer products include DOXO Rubicin, an anti-cancer chemotherapy drug; IDARUBICIN, an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug; Daunorubicin, which is used to treat acute lymphocytic and myelocyticleukemias; IMATINIB, a drug used to treat certain cancers, and EPI Rubicin, an anthracycline drug used for chemotherapy. The Companys other products include DACARBAZINE, which is used to treat Hodgkin disease and malignant melanoma; Temozolamide, an oral alkylating agent used for the treatment of Grade IV astrocytoma, and Simvastatin, a lipid lowering drug. Sterling Biotechs manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting CEP for the active pharmaceutical ingredient Epirubicin , Lovastatin;.
Sterling Biotech's top competitors include Laurus Labs, Symbiotec and SeQuent.
Sterling Biotech has 1 investor. Key investors include Perfect Day.
Sterling Biotech operates through Sterling Biotech Limited.
Yes. Sterling Biotech was acquired by Perfect Day in April 2022.
The legal entities of Sterling Biotech currently have 8 directors, including Monisha Prabhu Macedo, Vishal Jyotindra Gor, Keyur Anilkumar Parekh and others.